Screening, diagnosis and follow-up of Brugada syndrome in children: a Dutch expert consensus statement

P.J. Peltenburg*, Y.M. Hoedemaekers, S.A.B. Clur, N.A. Blom, A.C. Blank, E.P. Boesaard, S. Frerich, F. van den Heuvel, A.A.M. Wilde, J.A.E. Kammeraad

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Brugada syndrome (BrS) is a rare inherited arrhythmia syndrome. Affected children may experience life-threatening symptoms, mainly during fever. The percentage of SCN5A variant carriers in children is higher than in adults. Current diagnostic and follow-up policies for children with (a family history of) BrS vary between centres. Here, we present a consensus statement based on the current literature and expert opinions to standardise the approach for all children with BrS and those from BrS families in the Netherlands. In summary, BrS is diagnosed in patients with a spontaneous type 1 electrocardiogram (ECG) pattern or with a Shanghai score >= 3.5 including >= 1 ECG finding. A sodium channel-blocking drug challenge test should only be performed after puberty with a few exceptions. A fever ECG is indicated in children with suspected BrS, in children with a first-degree family member with definite or possible BrS according to the Shanghai criteria with a SCN5A variant and in paediatric SCN5A variant carriers. In-hospital rhythm monitoring during fever is indicated in patients with an existing type 1 ECG pattern and in those who develop such a pattern. Genetic testing should be restricted to SCN5A. Children with BrS and children who carry an SCN5A variant should avoid medication listed at and fever should be suppressed. Ventricular arrhythmias or electrical storms should be treated with isoproterenol infusion.
Original languageEnglish
Pages (from-to)133-137
Number of pages5
JournalNetherlands Heart Journal
Volume31
Issue number4
Early online date1 Oct 2022
DOIs
Publication statusPublished - Apr 2023

Keywords

  • Brugada syndrome
  • DNA diagnostics
  • Family screening
  • Follow-up
  • Children
  • RISK STRATIFICATION
  • CLINICAL-FEATURES
  • YOUNG-PATIENTS
  • MANAGEMENT

Cite this